Brain Tumor, Pediatric Clinical Trial
Official title:
Improving Well-being Among Young Adult Survivors of Childhood Brain Tumor: A Randomized Controlled Trial of a Brief Internet-based Behavioral Activation Program
Verified date | February 2020 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effectiveness of an Internet-based, behavioral activation intervention to promote well-being in a young adult survivors of childhood brain tumor.
Status | Completed |
Enrollment | 139 |
Est. completion date | May 19, 2019 |
Est. primary completion date | May 19, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: - History of childhood brain tumor - Ages of 18 and 30 years. - Have regular access to the Internet - Provide an e-mail address Exclusion Criteria: - Those that do not meet the inclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Brain Tumor Foundation | New York | New York |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline PERMA-Profiler score at 2 weeks and 3 months | The PERMA-Profiler is a general measure of well-being (Butler & Kern, 2016). The PERMA-Profiler measures Seligman's (2011) five pillars of well-being: positive emotion, engagement, relationships, meaning, and accomplishment. The measure consists of 23 items, including three items for each domain. The health, negative emotion, loneliness, and overall happiness items act as filler questions and provide more information. Items are rated on an 11-point Likert scale ranging from 0 (never) to 10 (always), or 0 (not at all) to 10 (completely). Scores are calculated as the average of the items comprising each factor. Butler and Kern (2016) suggested that the multidimensional structure be retained, rather than condensing responses; however, a single well-being score may provide a global indication of well-being. Therefore, for the current study, total scores for each subscale will be calculated as well as the total scores. Change from baseline total score will be assessed. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change from baseline World Health Organization-Disability Assessment Schedule 2.0 score at 2 weeks and 3 months | Measures overall health, functioning, and disability. Total scores range from 0 to 24. Scores are summed with higher scores indicating greater functional disability severity. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change from baseline Life Satisfaction Scale (LiSat-9) score at 2 weeks and 3 months | To measure satisfaction with life, the Life Satisfaction Questionnaire (LiSat-9; Fugl-Meyer et al., 1991) will be included. The LiSat-9 has 9 items; including one general life satisfaction item. There 8 are domain-specific items for vocational situation, financial situation, leisure, contact friends, sexual life, activities of daily living, family life, and partnership relationship. Items are rated on an Likert scale ranging from 1 (very dissatisfying) to 6 (very satisfying). Scoring consists of calculating the mean score. Higher scores indicate greater satisfaction with life. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Perceived Stress Scale score at 2 weeks and 3 months | To measure perceived stress, the Perceived Stress Scale (PSS; Cohen & Williamson, 1988) will be used. The PSS is a widely used 10-item scale in which respondents rate how stressful (unpredictable, uncontrollable, and overloaded) they perceive their lives to have been within the past month. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). Scoring consists of calculating the mean score. Higher scores indicate greater perceived stress. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Acceptance and Action Questionnaire (AAQ-II) score at 2 weeks and 3 months | The Acceptance and Action Questionnaire (AAQ-II) (Bond et al., 2011) consists of seven items to be answered on a scale of 1 (never true) to 7 (always true). The AAQ-II measures participants' willingness to live in accordance with their values, in contact with negative private events, and acceptance of these events. A higher total score indicates a higher level of psychological flexibility, that is higher acceptance and less experiential avoidance. Total mean score will be calculated. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Behavioral Activation for Depression Scale (BADS-9) score at 2 weeks and 3 months | The Behavioral Activation for Depression Scale- Short Form (BADS-9) is a 9-item scale with scores ranging from 0 to 54, with high scores representing higher activation. Total mean scores will be calculated. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Cognitive-Behavioral Social Self-Efficacy Scale score at 2 weeks and 3 months | The Cognitive-Behavioral Social Self-Efficacy Scale is an 18-item measure of perceived social self-efficacy. Item scores range from 1 (not confident at all) to 5 (very confident. Total scores range from 18 to 90, with higher scores representing greater perceived social self-efficacy. Total mean scores will be calculated. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Vocational Outcomes Expectancy Scale score at 2 weeks and 3 months | The Vocational Outcome Expectancy Scale (VOES) measures outcome expectancy related to employment. It is an 11-item scale with item scores ranging from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 11 to 55, with higher scores representing a greater expectation of attaining positive employment outcomes (i.e., obtaining or retaining employment). Total mean scores will be calculated. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline Perceived Barrier Scale score at 2 weeks and 3 months | The Perceived Career Barriers measure was developed to identify barriers to career development and employment of young adult survivors of pediatric brain tumors (Strauser et al., 2018). The 12-item measure uses an 11-point Likert Scale (0-10) with 0 being (not a barrier) and 10 being a (major barrier). A midpoint label of (somewhat of a barrier) is utilized. Total scores range from 0 to 110, with higher scores indicating greater perceived career barriers. | At baseline; 2 weeks and 3 months after completing the intervention. | |
Secondary | Change in baseline General Self-Efficacy Scale score at 2 weeks and 3 months | The General Self-Efficacy Scale (GSES) is a measure of general self-efficacy. It is a 10-item measure with item scores ranging from 1 (not true at all) to 4 (exactly true). Total scores range between 10 and 40, with a higher score indicating more self-efficacy. | At baseline; 2 weeks and 3 months after completing the intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 | |
Recruiting |
NCT04738162 -
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 | |
Recruiting |
NCT05709522 -
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
|
||
Recruiting |
NCT04722237 -
Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
|
N/A | |
Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
Recruiting |
NCT04670016 -
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
|
||
Active, not recruiting |
NCT03086421 -
Social Emotional Development in Young Children With Cancer
|
||
Active, not recruiting |
NCT03361033 -
Components of Social Functioning in Survivors of Pediatric Brain Tumors
|
||
Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
Recruiting |
NCT05672043 -
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
|
||
Recruiting |
NCT05553899 -
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
|
N/A | |
Withdrawn |
NCT04019470 -
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
|
||
Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
Suspended |
NCT05169944 -
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
|
Phase 1 |